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A B S T R A C T
Purpose
Preclinical data support a key role for the PI3K pathway in estrogen receptor–positive breast cancer
and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This
preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can
increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify themost
appropriate patient population for combination therapy.
Patients and Methods
In this randomized, open-label phase II trial, postmenopausal women with newly diagnosed
operable estrogen receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative
breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination)
to 2weeks of preoperative treatment with anastrozole 1mg once per day (n = 26) or the combination
of anastrozole 1mgwith pictilisib 260mg once per day (n = 49). The primary end point was inhibition
of tumor cell proliferation as measured by change in Ki-67 protein expression between tumor
samples taken before and at the end of treatment.
Results
There was signiﬁcantly greater geometric mean Ki-67 suppression of 83.8% (one-sided 95%CI,$ 79.0%)
for the combination and 66.0% (95% CI, # 75.4%) for anastrozole (geometric mean ratio [combination:
anastrozole], 0.48; 95%CI,# 0.72;P= .004). PIK3CAmutationswerenot predictive of response topictilisib,
but there was signiﬁcant interaction between response to treatment and molecular subtype (P = .03); for
patientswith luminal B tumors, the combination:anastrozole geometricmean ratio of Ki-67 suppressionwas
0.37 (95%CI,# 0.67;P= .008), whereas no signiﬁcant Ki-67 responsewas observed for pictilisib in luminal
A tumors (1.01; P = .98). Multivariable analysis conﬁrmed Ki-67 response to the combination treatment of
patients with luminal B tumors irrespective of progesterone receptor status or baseline Ki-67 expression.
Conclusion
Adding pictilisib to anastrozole signiﬁcantly increases suppression of tumor cell proliferation in
luminal B primary breast cancer.
J Clin Oncol 34:1987-1994. © 2016 by American Society of Clinical Oncology
INTRODUCTION
There is increasing evidence that aberrant
signaling through the PI3K-mTOR signaling
pathway plays a critical role in endocrine
resistance.1 The PI3K-mTOR pathway is the
most frequently altered pathway in estrogen
receptor (ER)–positive breast cancer.2,3 Aberrant
activation can occur through various mecha-
nisms, including activating mutations or am-
pliﬁcation of the PI3K catalytic subunits p110a
(PIK3CA) and p110b (PIK3CB), the effectors
AKT1, AKT2, or PDK1, or upstream receptor
tyrosine kinases such as human epidermal growth
factor receptor 2 (HER2), EGFR, or FGFR1, or
through loss of the negative regulators PTEN
or INPP4B.1-4
© 2016 by American Society of Clinical Oncology 1987
VOLUME 34 • NUMBER 17 • JUNE 10, 2016
134.36.50.219
Information downloaded from jco.ascopubs.org and provided by at University of Dundee on October 12, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
Surprisingly, activating mutations of PIK3CA have been shown
to be associated with improved patient outcome in ER-positive
breast cancer.5,6 Conversely, PIK3CA mutations have not been
shown to be predictive of response to endocrine treatment or
mTOR-targeted therapies.7,8 However, preclinical studies suggest
that PIK3CA mutations are predictive of sensitivity to PI3K
inhibitors but do not explain all of the sensitivity observed.9
Molecular proﬁling of ER-positive cancers demonstrated sub-
stantial overlap in gene signatures of PI3K activity between
PIK3CA mutant and wild-type tumors, suggesting that other
mechanisms aside from mutational activation of PIK3CA may
drive signaling through the pathway8 and emphasizing the
challenges of patient stratiﬁcation in a pathway with multiple
regulatory nodes and extensive crosstalk with other signaling
networks.10 These data highlight the need for comprehensive
molecular proﬁling of ER-positive cancers to identify biomarkers
of response to PI3K inhibitors and to characterize patients most
likely to beneﬁt from this therapy.
Multiple lines of preclinical and clinical investigation dem-
onstrate that inhibition of the PI3K-mTOR pathway can improve
the efﬁcacy of endocrine treatment.4,11-14 The OPPORTUNE
(Randomised Phase II Window Study of Short-Term Preoperative
Treatment With the PI3K Inhibitor GDC-0941 Plus Anastrozole
Versus Anastrozole Alone in Patients With ER-Positive Primary
Breast Cancer) trial was designed to assess whether addition of the
pan-PI3K inhibitor pictilisib (PIC; GDC-0941) could increase the
antiproliferative effects of short-term, preoperative treatment with
anastrozole (ANA) in ER-positive primary breast cancer. Short-
term preoperative studies are a validated strategy for evaluating the
impact of targeted therapies alongside endocrine agents by using
the nuclear proliferation marker Ki-67 as a surrogate end point of
treatment beneﬁt.15-20 Access to tumor tissue before and after
treatment enables comprehensive analysis of biomarker changes,
thus providing critical insights into the optimal patient population,
biomarker responses, and potential mechanisms of resistance.
PATIENTS AND METHODS
Study Design
OPPORTUNE was an open-label, randomized phase II trial per-
formed in 10 academic medical centers in the United Kingdom. The study
had two primary aims: to detect an increase in Ki-67 suppression with PIC
in ER-positive patients and to assess the treatment effects in subgroups
deﬁned by PI3K mutations, luminal A/B subtypes, and baseline Ki-67
scores. The main analysis of the overall treatment effects was planned with
70 evaluable patients and is reported here. A second, more comprehensive
biomarker analysis will be performed with 141 patients to provide more
power for subgroup analyses.
Patients were eligible if they were postmenopausal and had histo-
logically diagnosed ER-positive, HER2-negative invasive breast cancer. ER
positivity was deﬁned as $ 1% of tumor cells positive on immunohis-
tochemistry (IHC) or an Allred IHC score of$ 3. All patients had operable
breast cancer $ 1 cm in diameter; adequate hematologic, hepatic, and
renal function; and baseline fasting plasma glucose of, 7.8 mmol/L. Prior
treatment of breast cancer or use of hormone replacement therapy was not
permitted. Patients with inﬂammatory cancer or distant metastases were
excluded. In addition, patients with signiﬁcant pulmonary dysfunction,
cardiac disease, or diabetes mellitus were excluded. The trial was approved
by the United Kingdom Medicines and Healthcare Products Regulatory
Agency and the London City East Research Ethics Committee (11/LO/
1559). All patients provided written informed consent.
Randomization
Patients were randomly assigned (2:1, favoring the combination) to
receive treatment with ANA or ANA + PIC. Computer-generated per-
muted blocks were used, and stratiﬁcation was by center and histologic
grade, as assessed on the diagnostic core biopsy. Participants and inves-
tigators were aware of assignment but the investigators who measured the
biomarkers were blinded.
Treatment
ANA was given at a dose of 1 mg once per day. PIC was initially
administered at 340 mg once per day; from August 2012 onward, PIC was
reduced to 260 mg once per day according to safety data from other studies
that indicated a lower rate of mucosal and skin toxicity at 260 mg. Five
evaluable patients received PIC 340 mg; the remaining patients received
PIC 260 mg. Study treatment was given for 14 days, followed by surgical
resection and adjuvant therapy as appropriate for each patient according to
local practice guidelines.
At least two core-cut tumor biopsies were taken at baseline and at the
end of treatment. The last dose of study medication was required within 2
to 4 hours before the end-of-treatment biopsy. Formalin-ﬁxed parafﬁn-
embedded cores were placed into 10% buffered formalin within 10 minutes
and ﬁxed for$ 6 hours before further processing. Snap frozen cores were to
be placed in liquid nitrogen within 10 minutes.
All tumor core biopsies were reviewed centrally. IHC was performed
on 3- to 4-mm sections after heat-mediated antigen retrieval. Antibodies
for Ki-67 (Clone 30-9, Ventana Medical Systems, Tucson, AZ), cleaved
caspase-3 (Clone Asp175, Cell Signaling Technology, Danvers, MA),
progesterone receptor (PgR; Clone 1E2, Ventana), and PTEN (Clone
138G6, Cell Signaling Technology) were used. Ki-67 and caspase-3 IHC
results were recorded independently by two investigators who were blinded
regarding treatment allocation and each other’s assessment. At least
Patients screened
 (N = 88)
Screening failures
(n = 13) 
Randomly assigned
(n = 75)
Assigned to
anastrozole
(n = 26)
Assigned to pictilisib
plus anastrozole
(n = 49)
Excluded                                                    (n = 2)
   1 HER2-positive        (n = 1)
      breast cancer         
   1 tumor size < 1 cm  (n = 1)
Treated with
anastrozole
(n = 26)
Treated with pictilisib
plus anastrozole
(n = 47)
Evaluable
(n = 26)
Evaluable
(n = 44)
Excluded                    (n = 3)
   AEs                          (n = 2)
   Insufficient tissue  (n = 1)
Fig 1. Trial CONSORT diagram. AE, adverse event; HER2, human epidermal
growth factor receptor 2.
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1,000 invasive cancer cells were counted for Ki-67 analysis; Ki-67 was scored
as the percentage of positively stained cells. A cutoff of 14% was selected to
deﬁne high and low baseline Ki-67 expression, but alternative cutoffs (10%
and 20%) were also evaluated.21,22 For caspase-3, at least 3,000 cells were
assessed. PgR was assessed centrally and regarded as positive if Allred score
was $ 3. PTEN was classiﬁed as positive if any cytoplasmic and/or nuclear
expression was observed in tumor cells and negative if no immune reactivity
was observed, with the stroma serving as a positive internal control.
Molecular breast cancer subtype was deﬁned by using the NanoString
PAM50 algorithm23 (Data Supplement). PIK3CA mutations were assessed
by targeted next-generation sequencing by using the Ampliseq Compre-
hensive Cancer panel assay with the Ampliseq Library Kit 2.0 according
to the manufacturer’s instructions (Ion Torrent, Life Technologies,
Gaithersburg, MD).
Statistical Analysis
The sample size was based on the two primary aims. The ﬁrst analysis
was planned for 70 evaluable patients providing 80% power at the 5%
signiﬁcance level (one-sided) to detect an effect size of 0.77 between ANA
and ANA + PIC. Effect size was deﬁned as (MANA + PIC – MANA)/spooled,
where MANA + PIC and MANA are geometric mean Ki-67 suppression values
and spooled is equal to the square root of [(sANA + PIC
2 + sANA
2)/2]. The
study was also planned to detect a 20% difference in RKi-67-day 15 and RDKi-67
response rates between arms. The proportion of responders in the com-
bination group was assumed to be 60% under the null hypothesis and 80%
under the alternative hypothesis; the test statistic used is the one-sided Z test
with pooled variance giving a power of 86%.
All analyses regarding Ki-67 changes were performed on a per-
protocol population, deﬁned as all patients who completed 2 weeks of
treatment and for whom tumor biopsy specimens were available for
assessment of biologic response.
The primary end point was change in Ki-67. Primary Ki-67 analysis
was based on estimating the mean Ki-67 suppression in each group and the
geometric mean ratio of proportional changes between groups. Geometric
means were used because of the approximate lognormal distribution of the
data. Values at day 15 were expressed as geometric mean proportions of
the baseline and transformed into mean suppression (deﬁned as one minus
the geometric means of the proportional changes).
Secondary Ki-67 analyses were geometric mean end-of-treatment
Ki-67 expression, individual end-of-treatment antiproliferative response
(RKi-67 day 15) deﬁned as Ln(Ki-67day 15) # 2, and individual anti-
proliferative response (RDKi-67) deﬁned as a $ 50% decrease in Ki-67
expression.16,24 Secondary end points were safety, tolerability, and
changes in the apoptosis marker caspase-3; caspase-3 analyses included
geometric mean change in caspase-3 between day 15 and baseline and
individual apoptotic response (RDcasp3) deﬁned as a $ 50% increase in
caspase-3 IHC.
The ratio of the geometric means of the proportional changes and the
end-of-treatment Ki-67 expression between groups was analyzed by using
t tests. RKi-67 day 15 and RDKi-67 response rates and one-sided 95% CIs were
calculated separately for each arm and compared by using Fisher’s exact
test. The relative risk and the associated 95% CI were calculated based on a
Mantel-Haenszel heterogeneity x2 test.
Safety data were reported for all patients who received at least one
dose of the study treatment. The worst grade of any adverse event (AE)
during trial treatment was reported and compared between trial arms by
using Fisher’s exact test.
Multivariable linear regression models based on univariate analyses
were conducted to determine which molecular parameters were predictive
and/or prognostic for the disease. Ln(Ki-67day 15/Ki-67baseline) was
modeled as a dependent variable. On the basis of univariable analyses,
treatment, molecular subtype, PgR status, and their interaction with
treatment were included. No demographic or stratifying factors were
associated with outcome or improved the model ﬁt. PIK3CAmutation and
baseline Ki-67 expression showed little effect on outcome and were not
included in the ﬁnal model (Data Supplement).
RESULTS
Between January 2012 and September 2014, 75 patients were
randomly assigned (Fig 1). Two patients were excluded because of
violations of key eligibility criteria. Assessment of the treatment
effects was possible for 70 patients who successfully completed
the protocol; two patients in the combination arm discontinued
Table 1. Patient Demographic and Tumor Characteristics at Baseline
Characteristic
ANA Alone (n = 26) ANA + PIC (n = 44)
No. (%) Mean (range) No. (%) Mean (range)
Age (years) 68.7 (48.9-85.4) 67.5 (49.2-83.0)
Size of primary tumor, cm 20.2 (10-36) 20.7 (10-50)
Tumor grade
1-2 22 (84.6) 37 (84.1)
3 4 (15.4) 7 (15.9)
PgR status
Positive 16 (64.0) 29 (95.1)
Negative 9 (36.0) 2 (4.9)
Molecular subtype
Luminal A 6 (31.6) 14 (41.2)
Luminal B 13 (68.4) 20 (58.8)
Ki-67 (% positive tumor cells) 25.0 (4.4-68.7) 22.6 (2.7-67.8)
0-14 9 (34.6) 17 (38.6)
.14 17 (65.4) 27 (61.4)
PIK3CA mutation status
Wild-type 14 (60.8) 24 (60.0)
Mutation 9 (39.1) 16 (40.0)
Kinase domain mutation 5 (21.7) 9 (22.5)
Helical domain mutation 3 (13.0) 6 (15.0)
NOTE. Kinase domain mutations include H1047R/Y, H1048R, and G1049D/R; helica -domain mutations include E524K and E545K.
Abbreviations: ANA, anastrozole; PgR, progesterone receptor; PIC, pictilisib.
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treatment early because of AEs and one patient had insufﬁcient
tissue for analysis. Baseline distributions of patient and tumor
characteristics were similar in the treatment arms (Table 1); 62% of
patients had luminal B tumors and 63% had a baseline Ki-67 score
of . 14%.
Tumor Ki-67 expression decreased in all but three patients
from baseline to day 15 (Fig 2A-B); mean percentage suppression
of Ki-67 was 83.8% (95% CI, $ 79.0%) for patients treated with
ANA+ PIC and 66.0% (95%CI,# 75.4%) for patients treated with
ANA (Table 2 and Fig 3A). The ratio (ANA + PIC:ANA) of mean
Ki-67 suppression was 0.48 (95% CI,# 0.72; P = .004). The mean
end-of-treatment Ki-67 expressionwas 2.9% (95%CI,# 3.7%) for
ANA + PIC and 6.1% (95% CI, $ 4.1%) for ANA (P = .005).
Individual RDKi-67 response rates were 86.4% (95% CI,
$ 77.%) for ANA + PIC and 53.9% (95% CI,# 69.9%) for ANA
(P = .003; Table 2). By using the deﬁnition that patients with
Ln(Ki-67day 15) # 2 represented an end-of-treatment response,
90.9% (95% CI, $ 83.8%) of patients treated with ANA + PIC
were responders compared with 61.5% (95% CI, # 77.2%) of
patients treated with ANA (P = .003).
Predeﬁned subset analyses investigated potential interactions
of PI3K mutations, luminal A/B subtypes, and baseline Ki-67
scores with Ki-67 response. Given the limited power of these
analyses, results must be considered exploratory and interpreted
with caution.
At least one PIK3CA mutation was detected in 25 tumors
(39.7%), including 14 helical domain and nine kinase domain
mutations. There was no signiﬁcant correlation between PIK3CA
mutations and the activity of PIC (Figs 3C and 4); interestingly, the
small number of helical domain mutants showed a relatively poor
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Fig 2. Individual Ki-67 changes from
baseline to day 15. (A) Individual changes in
percentage Ki-67 expression from baseline
to day 15; the number and percentage of
patients achieving an end-of-treatment
(EOT) Ki-67 score of . 10% or # 10% are
provided for each group. (B) Individual rel-
ative Ki-67 suppression sorted from low to
high; relative Ki-67 suppression is deﬁned as
Ln(Ki-67day 15) – Ln(Ki-67baseline); results are
displayed on their original scale by back
transformation. Individual PTEN status,
PIK3CA status, progesterone receptor (PgR)
status, luminal A/B status, tumor grade,
baseline and EOT Ki-67 expression are indi-
cated by colored boxes under each patient.
IHC, immunohistochemistry; mut, mutant;
Wt, wild-type.
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response to ANA but a good response to ANA + PIC (mean Ki-67
suppression, 46.2% v 82.7%; ratio [ANA + PIC:ANA], 0.32
[95% CI, # 0.73]; P = .03; Fig 3C).
Subgroup analysis showed that patients with PAM50 luminal
B tumors had a signiﬁcantly higher antiproliferative response with
ANA + PIC compared with ANA (mean Ki-67 suppression,
86.5% v 63.6%; ratio [ANA + PIC:ANA], 0.37; 95% CI, # 0.67;
P = .008), whereas adding PIC had no apparent beneﬁt for luminal
A tumors (ratio, 1.01; P = .98; Figs 3B and 4). Multivariable analysis
conﬁrmed signiﬁcant interaction between treatment effect and
molecular subtype (P = .03), conﬁrming the hypothesis that Ki-67
suppression is higher with ANA + PIC treatment than with ANA
for patients with luminal B tumors irrespective of PgR status or
baseline Ki-67 expression. Patients with PR-negative luminal B
cancers showed the greatest antiproliferative effect from treatment
with ANA + PIC (ratio, 0.12). Furthermore, combined treatment
also appeared to be more effective in PgR-negative luminal A
cancers. There was no difference between baseline and end-of-
treatment apoptosis levels between treatment groups (geometric
mean caspase-3 change, –10.4% for ANA + PIC and –13.9% for
ANA; ratio, 0.96; P = .90).
Treatment-related AEs were consistent with those previously
described for PIC and ANA with more AEs in the PIC-treated
group (Table 3). No pulmonary toxic effects associated with PIC
were identiﬁed. Reducing PIC dose from 340 mg to 260 mg
reduced the skin toxicity signiﬁcantly (grade 3, 38% v 3.3%;
P =.013). At a PIC dose of 260 mg, grade 3 AEs were asymptomatic
hyperglycemia and rash in one patient each. Treatment was dis-
continued in two patients receiving 340 mg PIC because of
hypersensitivity reaction and rash. AEs were rapidly reversible, and
all patients received subsequent standard therapy as planned.
DISCUSSION
OPPORTUNE is the ﬁrst trial of a PI3K inhibitor in ER-positive
early-stage breast cancer. The study successfully met the primary
end point, demonstrating that adding PIC to ANA signiﬁcantly
increased the antiproliferative response. Both mean Ki-67 sup-
pression and the percentage of tumors with signiﬁcant Ki-67
reduction were substantially higher for ANA + PIC compared
with ANA. Most importantly, the end-of-treatment Ki-67 sup-
pression was also signiﬁcantly higher for ANA + PIC. This is
particularly relevant because only end-of-treatment Ki-67 expression
but not baseline expression has been associated with improved
recurrence-free survival (RFS).16 In the IMPACT (Immediate Pre-
operative Anastrozole, Tamoxifen, or Combined with Tamoxifen)
trial, 5-year RFS rates were 85%, 75%, and 60%, respectively, for the
lowest, middle, and highest tertiles of Ki-67 expression after 2 weeks of
preoperative endocrine therapy.16 End-of-treatment Ki-67 expression
seems to integrate the prognostic value of baseline proliferation and
the predictive value of responding to endocrine therapy, thus making
it an excellent predictor of outcome in this setting.16
We also investigated the interaction between antiproliferative
response and PIK3CA mutations. In keeping with other series,2,6
approximately 40% of tumors carried a mutation in the PIK3CA
gene, 84% of these in one of the hotspots in the helical and kinase
domains. Baseline Ki-67 expression was comparable between wild-
type and mutant samples (23.3%, 20.7%, and 25.5% for wild-type,
helical, or kinase mutations), conﬁrming previously reported
results.25,26 There was no association between PIK3CA mutation
status and antiproliferative response to ANA, in keeping with other
studies suggesting that PIK3CA mutations have limited impact on
endocrine therapy.8,25,26 Our data suggest that PIK3CA mutations
are also not associated with increased antiproliferative response for
ANA + PIC. This is consistent with results from trials of PIC or
everolimus in metastatic breast cancer.7,27,28 Interestingly, tumors
with helical or kinase domain mutations appeared to respond
differently (Ki-67 suppression ratio: helical, 0.32 [95% CI,# 0.73];
kinase, 0.76 [95% CI,# 1.63]). A similar observation was reported
in a neoadjuvant trial of everolimus in ER-positive breast cancer in
which helical domainmutations were also associatedwith an increased
beneﬁt.24 This observation may merit testing in future studies.
Preplanned subset analyses suggest that the additional anti-
proliferative effects of PIC may largely be limited to luminal B
tumors, whereas luminal A tumors demonstrated no additional effect
unless they were PgR negative. The latter result has to be seen in the
context that negative PgR status and luminal B subtype are closely
associated. Multivariable analysis also suggested that the impact of
molecular subtype was independent of baseline proliferation. This is
relevant because the PAM50 classiﬁcation includes genes from the ER
response pathway as well as cell cycle progression. Consequently,
there is a link between PAM50 subtypes and Ki-67 expression, but
overlap is incomplete. In theOPPORTUNE trial, the discordance rate
between baseline Ki-67 expression and PAM50 classiﬁcationwas 21%
by using a cutoff of 14%, and there was only a weak interaction
between baseline Ki-67 and response to PIC (Data Supplement).
Overall, these ﬁndings are supportive of an association between
luminal B subtype, insensitivity to endocrine treatment, and anti-
proliferative response to treatment with PIC, which has implications
Table 2. Antiproliferative Response to ANA or ANA + PIC
Response ANA (n = 26)% (95% CI) ANA + PIC (n = 44)% (95% CI) Relative Risk (combination/ANA) P
Geometric mean Ki-67 suppression 66.0 (# 75.4) 83.8 ($ 79.0) 0.48* (# 0.72) .004
Geometric mean EOT Ki-67 expression 6.1 ($ 4.1) 2.9 (# 3.7) 0.48* (# 0.73) .005
RDKi-67 response rate 53.9 (# 69.9) 86.4 ($ 77.8) 1.60 ($ 1.17) .003
RKi-67 day 15 response rate 61.5 (# 77.2) 90.9 ($ 83.8) 1.48 ($ 1.13) .003
NOTE. Geometric mean Ki-67 suppression is deﬁned as Ln(Ki-67day15) – Ln(Ki-67baseline); the ratio (combination/ANA) of geometric mean Ki-67 suppression is provided
with 95%CI. Geometric mean end-of-treatment (EOT) Ki-67 expression is deﬁned as Ln(Ki-67day 15); individual EOT antiproliferative response RKi-67 day 15 is deﬁned as Ln
(Ki-67day 15) # 2; individual antiproliferative response RDKi-67 is deﬁned as a $ 50% fall in Ki-67 expression between baseline and day 15.
Abbreviations: ANA, anastrozole; PIC, pictilisib.
*Geometric mean ratio of Ki-67 proportional changes between the groups.
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for future trial design. However, given the limited power, additional
conﬁrmation from the ﬁnal analysis should be awaited before
deﬁnitive conclusions can be drawn.
As expected, the rate of apoptosis was low, with themajority of
tumors containing , 1% apoptotic cells. No differences were
observed between treatment groups, but the strong correlation
between Ki-67 and apoptosis scores found in this and other trials16
could mask an effect of PI3K inhibition on apoptosis as observed in
preclinical studies.12
Although the OPPORTUNE trial showed an increased
response with ANA + PIC in early breast cancer, the FERGI (A
Phase II, Double-Blind, Placebo-Controlled, Randomized Study of
GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in
Advanced or Metastatic Breast Cancer in Patients Resistant to
Aromatase Inhibitor Therapy) trial failed to demonstrate a sig-
niﬁcant beneﬁt of adding PIC to fulvestrant in metastatic disease.
This may have been related to the lower dose of PIC, with 23.6% of
patients requiring dose modiﬁcations and 34% discontinuing PIC.28
Because the OPPORTUNE trial did not allow dose modiﬁcations
and excluded patients who discontinued treatment before surgery,
results might reﬂect the potential of PI3K inhibitors if a sufﬁcient
dose can be maintained. Alternative strategies to speciﬁcally target
the alpha subunit of PI3K, whichmay have awider therapeutic index
than pan-PI3K inhibitors, might overcome these limitations.
There are a few caveats with respect to the data presented here.
First, the study was not sufﬁciently powered for detailed subset
analyses, and there is a risk of false-positive ﬁndings. Second,
baseline PgR status was imbalanced between treatment arms with
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Fig 3. Antiproliferative response to study treatment. (A) Antiproliferative response expressed as the geometric mean Ki-67 suppression from baseline to day 15. (B)
Antiproliferative response by luminal subtype. (C) Antiproliferative response by PIK3CA mutation status; e9: exon 9 domain mutations (helical domain); e20: exon 20
domainmutations (kinase domain). (D) Antiproliferative response at day 15 compared with baseline. The cumulative proportion (by percentage) of patients who had tumors
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indicate 95% CI. wt, wild-type.
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fewer PgR-negative tumors in the combination arm; this limits the
study’s ability to verify results from the recent FERGI study subset
analysis, which suggested that only PgR-positive patients beneﬁt
from PI3K. Third, not all patients in the combination arm received
the same dose of PIC. However, mean Ki-67 suppression was
comparable for patients treated with 340 mg (68.8%) and 260 mg
(76.7%). Finally, although previous studies have clearly established
an association between Ki-67 response and RFS, it is unclear to
what degree the same applies for combinations of endocrine
treatment with other agents. Results of the OPPORTUNE trial
therefore must be interpreted with caution in terms of potential
long-term beneﬁts.
Overall, the OPPORTUNE trial is, to the best of our knowledge,
the ﬁrst study to demonstrate that addition of the pan-PI3K inhibitor
PIC signiﬁcantly increases the antiproliferative response to ANA in
ER-positive early-stage breast cancers. PIK3CA mutations were not
predictive of response to PIC, although patients with exon 9 mutation
showed a particularly poor response to ANA that was reversed by the
addition of PIC. Luminal B and PgR-negative cancers may enrich for
tumors, with the most antiproliferative effect with ANA + PIC.
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Fig 4. Ratio (combination:ANA) of geo-
metricmean of Ki-67 proportional changes in
prespeciﬁed subgroups. Pgr, progesterone;
WT, wild type.
Table 3. Adverse Events in the Safety Population
Most Common Adverse Events*
ANA Alone
(n = 26)
ANA + PIC (340 mg)
(n = 8)
ANA + PIC (260 mg)
(n = 39)
G1/2 G3 G1/2 G3 G1/2 G3
No. % No. % No. % No. % No. % No. %
Fatigue 6 23 1 4 7 88 0 6 26 0
Rash 0 0 2 25 3 38† 3 8 1 3
Diarrhea 1 4 0 4 50 0 20 52 0
Dysgeusia 1 4 0 2 25 0 4 10 0
Dyspepsia 0 0 1 13 0 7 18 0
Anorexia 1 4 0 2 25 0 5 13 0
Nausea 3 12 0 7 88 0 16 41 0
Vomiting 0 0 2 25 0 5 13 0
Stomatitis 0 0 1 13 0 2 5 0
Hyperglycemia 0 0 0 0 3 8 1 3
Creatinine 0 0 3 38 0 3 8 0
Arthralgia 5 19 0 1 13 0 1 3 0
Headache 4 16 0 1 13 0 3 8 0
Hot ﬂashes 6 23 0 0 0 2 5 0
NOTE. The safety population includes all patients who received at least one dose of the study drug.
Abbreviations: ANA, anastrozole; G, grade; PIC, pictilisib.
*Included are all adverse events with an incidence of 10% or more in either group.
†Fisher’s exact P = .013 between PIC 340 mg and 260 mg.
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